Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» neuropsychiatric
neuropsychiatric
Neurocrine Hit with Back-to-Back Phase II Failures in Neuropsychiatry
Neurocrine Hit with Back-to-Back Phase II Failures in Neuropsychiatry
BioSpace
Neurocrine
neuropsychiatric
clinical trials
focal onset seizures
major depressive disorder
NBI-921352
NBI-1065846
Flag link:
Harmony Makes Rare Disease Play with Potential $200M Zynerba Buyout
Harmony Makes Rare Disease Play with Potential $200M Zynerba Buyout
BioSpace
Harmony Biosciences
Zynerba
M&A
neuropsychiatric
Flag link:
Boehringer Ingelheim to surf with Melbourne-based biotech in $181M neuropsychiatric therapy deal
Boehringer Ingelheim to surf with Melbourne-based biotech in $181M neuropsychiatric therapy deal
Fierce Biotech
Boehringer Ingelheim
Kinoxis Therapeutics
neuropsychiatric
Flag link:
Sunovion pens $890M Otsuka pact for a clutch of neuropsychiatric drugs
Sunovion pens $890M Otsuka pact for a clutch of neuropsychiatric drugs
Fierce Biotech
Sunovion
Otsuka
biobucks
neuropsychiatric
Flag link:
